I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

WCLC 2024

-
Coming soon
05:57 PM
Duration 10mins 20A
IMpower010 5-y subgroup analysis and relapse patterns: Phase 3 study of atezolizumab vs BSC in stage II-IIIA NSCLC
Felip E, Wakelee HA, Vallieres E, Martinez-Marti A, Goloborodko O, Zhou C, Rittmeyer A, Chella A, Reck M, Csoszi T, Bondarenko I, Kenmotsu H, Shutte W, Ding B, Zhu C, Ballinger M, Bennett E, Gitlitz BJ, Altorki N
10:00 AM
Duration 2hrs San Diego, USA
Divarasib versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell lung Cancer (NSCLC)
Shirish M. Gadgeel, Uyi Osaghae, Ahmadur Rahman, Tharu M. Fernando, Mark T. Lin, Kalpesh Koli, Christoph Meyenberg, Michael Mathisen, Ferdinandos Skoulidis
01:15 AM
Duration 90mins San Diego, USA
LCMC3: Clinical Utility of SUVmax on Preoperative 18F-FDG PET-CT in Resectable NSCLC Treated with Neoadjuvant Atezolizumab
B Merritt, D Carbone, E Toloza, J Lee, A Patterson, V Rusch, B Johnson, P Bunn, K Schulze, A Nicholas, A Johnson, D Owen
10:30 PM
Duration 45mins 20A
ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)
Hidehito Horinouchi, Benjamin J. Solomon, Yi-Long Wu, Fabrice Barlesi, Makoto Nishio, Jin Seok Ahn, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, Maximilian Hochmair, Igor Bondarenko, David Planchard, Achim Rittmeyer, Beiying Ding, Thorsten Ruf, Leah Adler, Astrid Scalori, Rafal Dziadziuszko
Duration 45mins 20D
Divarasib single-agent long-term follow-up and atezolizumab combination treatment in patients with KRAS G12C-positive NSCLC
Sacher A, Wilson H. Miller Jr., Luis Paz-Ares, Myung-Ju Ahn, Manish R. Patel, Rafal Dziadziuszko, Armando Santoro, Jia Luo, Ben Markman, Pierre Freres, Marloes Van Dongen, Jayesh Desai, Samantha Bowyer, Andres Cervantes, Josiane Mourão Dias, Alejandro Falcon, Matthew G. Krebs, Scott Laurie, Hans Prenen, Ruth Perets, Erminia Massarelli, Se Hyun Kim, Maria De Miguel, Sanjeev Deva, Elena Garralda, Laura Medina, João Daniel Guedes, Salvatore Siena, Tormod Guren, Eugenio Fernandez, Loes Latten Jansen, Rita De Cassia Costamilan, Yoonha Choi, Sandhya Mandlekar, Mark T. Lin, Kenneth K. Yau, Julie Chang, Stephanie Royer-Joo, Tomi Jun, Neekesh V. Dharia, Jennifer L. Schutzman, Patricia Lorusso
10:35 PM
Duration 75mins 20A
LCMC3: Long-term disease-free and overall survival and their association with ctDNA after neoadjuvant atezolizumab for NSCLC
D H. Owen, J E. Chaft, E B. Haura, E Toloza, S N. Waqar, G. A Patterson, D Finley, J Blasberg, D Raz, R Salgia, J M. Lee, P Bunn, I Wistuba, D J. Kwiatowski, F Hirsch, A Gopalakrishnan, A Batra, E Brandao, J Grindheim, A Nicholas, A Johnson, K Schulze, E Shum, M Nagasaka, J Gainor, C J. McNamee, B E. Johnson, M G. Kris, V W. Rusch, D P. Carbone